¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"enzyme antagonist"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® serum enzyme ÇÑ±Û Ç÷ûȿ¼Ò
¼³¸í   
  Ç÷û ³»¿¡ Æ÷ÇԵǾî Àִ ¿©·¯ °¡Áö È¿¼Ò¸¦ ÀÏÄ´ ¸»ÀÌ´Ù.
¿µ¹® enzyme ÇÑ±Û È¿¼Ò
¼³¸í   
  »ý¹°Ã¼ ¼¼Æ÷¼Ó¿¡¼­ ÇÕ¼ºµÇ°í, ÁַΠ¼¼Æ÷³»¿¡¼­ ÁøÇàµÇ´Â È­ÇйÝÀÀÀ» Ã˸ÅÇϴ ´Ü¹éÁú·Î ½ÃÇè°ü³»¿¡¼­µµ °°Àº Ã˸ÅÀÛ¿ëÀ» ÇÑ´Ù. ÀÌ È¿¼Ò´Â ÀΰøÀûÀ¸·Î ¸¸µç ¾î¶² Ã˸ÅÁ¦º¸´Ù ±× Æ¯À̼º°ú Ã˸ÅÀÛ¿ëÀ̠Ź¿ùÇѠƯº°ÇÑ »ýüºÐÀÚÀÌ´Ù. ½ÅÁø´ë»ç, Áï ¼¼Æ÷³»¿¡¼­ ÀϾ´Â ¹°ÁúÀÇ È­ÇÐÀû º¯È¯Àº È¿¼ÒÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ¸Å¿ì ºü¸£°í ¿øÇÒÇϰԠÀÌ·ç¾îÁø´Ù. À̰ÍÀº È¿¼ÒÀÇ Ã˸ŠȿÀ²ÀÌ ³ôÀº Á¡°ú È¿¼ÒÀÇ ±âÁú Æ¯À̼º ¶§¹®ÀÌ´Ù. È¿¼Ò¹ÝÀÀÀº »ó¿Â, »ó¾Ð, ÃÖÀû pH µî ÀûÀýÇÑ Á¶°Ç ¾Æ·¡¿¡¼­ ÁøÇàµÈ´Ù. ¶Ç È¿¼ÒÀÇ ÁÖü°¡ ´Ü¹éÁúÀ̱⠶§¹®¿¡ ´Ü¹éÁúÀ» º¯¼º½Ã۴ ¿­, °­»ê, °­¾ËÄ®¸®, À¯±â¿ë¸Å µî¿¡ ÀÇÇØ ±× ÀÛ¿ëÀ» ÀҴ´Ù. È¿¼Ò´Â »ýü¿¡ ³Î¸® ºÐÆ÷Çϸç, º¹ÀâÇÏ°í ´Ù¾çÇÑ ´ë»ç¹ÝÀÀÀ» Ã˸ÅÇϱ⠶§¹®¿¡ Á¾·ùµµ ¸¹´Ù. ¾Õ¼­ ¸»ÇÑ ¹Ù¿Í °°ÀÌ ´ëºÎºÐÀÇ È¿¼Ò´Â ¼¼Æ÷³»¿¡ Á¸ÀçÇÏÁö¸¸, Ç÷¾×°ú ±×¿ÜÀÇ °£Áú¾×¿¡ µé¾î Àֱ⵵ ÇÏ°í ¼ÒÈ­È¿¼Ò·ù󷳠ü¿Ü·Î ºÐºñµÇ´Â °Íµµ ÀÖ´Ù.
¿µ¹® enzyme-linked immunoabsorbent assay ÇÑ±Û È¿¼Ò¸é¿ªÃøÁ¤¹ý
¼³¸í   
  È¿¼Ò°áÇո鿪ÈíÂøÁ¦ °ËÁ¤¹ýÀ¸·Î ¹ø¿ªµÇ°í ÀÖ´Ù. ÀÌ ¹ýÀº Ç׿ø(¶Ç´Â Ç×ü)¿¡ ¾ËÄ®¸® Æ÷½ºÆÄŸ¾ÆÁ¦ ¶Ç´Â Æä¸£¿Á½Ãµð¾ÆÁ¦ µîÀÇ »ê¼Ò¸¦ °áÇÕ½ÃÄÑ µÎ°í ±× »ê¼ÒȰ¼ºÀ» ÁöÇ¥·Î »ï¾Æ Ç׿øÇ×ü¹ÝÀÀÀÇ Á¤µµ¸¦ ¾È ´ÙÀ½ ¿©±â¿¡¼­ Ç׿ø(¶Ç´Â Ç×ü)ÀÇ ¾çÀ» ±¸Çϴ °ÍÀÌ´Ù. ÀÌ ¹ýÀÇ ÀÌÁ¡À¸·Î¼­ °í°¨µµ, Á¶ÀÛÀÇ °£´ÜÇÔ ¹× ¹æ»ç¼±¸é¿ªÃøÁ¤¹ýó·³ ¹æ»ç¼º¹°ÁúÀ» »ç¿ëÇÏÁö ¾Ê¾Æµµ µÈ´Ù´Â Á¡À» µé ¼ö ÀÖ´Ù. È£¸£¸óÀ̳ª ¸é¿ª±Û·ÎºÒ¸°ÀÇ Á¤·®¹ýÀ¸·Î¼­ ÀÀ¿ë µÇ°í ÀÖÀ¸¸ç ÃøÁ¤¿ë Å°Æ®µµ ½ÃÆÇµÇ°í ÀÌÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    1. ´ëÇ×Á¦, ±æÇ×Á¦ 2. ´ëÇ×±Ù
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦, ¾Æµå·¹³¯¸°±æÇ×Á¦
  • competitive antagonist
    °æÀï´ëÇ×Á¦
  • contralateral antagonist
    ¹Ý´ëÂÊ´ëÇ×±Ù
  • direct antagonist
    Á÷Á¢´ëÇ×±Ù
  • dopaminergic antagonist
    µµÆÄ¹Î´ëÇ×Á¦, µµÆÄ¹Î±æÇ×Á¦
  • muscarinic antagonist
    ¹«½ºÄ«¸°´ëÇ×Á¦
  • narcotic antagonist
    ¸¶¾à´ëÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±Ù(À°)´ëÇ×Á¦
  • opioid antagonist
    ¾ÆÆíÀ¯»çÁ¦´ëÇ×Á¦
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • angiotensin converting enzyme
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • angiotensin converting enzyme inhibitor
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦
  • antibody capture enzyme-linked immunosorbent assay
    Ç×üÆ÷ȹȿ¼Ò¸é¿ªÃøÁ¤(¹ý)
  • autolytic enzyme
    ÀÚ°¡¿ëÇØÈ¿¼Ò
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    1.´ëÇ×Á¦, ±æÇ×Á¦, 2.´ëÇ×±Ù
  • enzyme-linked immunosorbent assay
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme
    È¿¼Ò
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • oxidative enzyme
    »êÈ­È¿¼Ò
  • proteolytic enzyme
    ´Ü¹éÁúºÐÇØÈ¿¼Ò
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò
  • redox enzyme
    »êȭȯ¿øÈ¿¼Ò
  • regulatory enzyme
    Á¶ÀýÈ¿¼Ò
  • respiratory enzyme
    È£ÈíÈ¿¼Ò
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    ´ëÇ×Á¦, ¸Â¹öÆÀÁ¦
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦
  • competitive antagonist
    °æÀï´ëÇ×¹°Áú
  • contralateral antagonist
    ¹Ý´ëÂÊ´ëÇ×±Ù
  • direct antagonist
    Á÷Á¢´ëÇ×±Ù
  • dopaminergic antagonist
    µµÆÄ¹Î´ëÇ×Á¦, µµÆÄ¹Î¸Â¹öÆÀÁ¦
  • ipsilateral antagonist
    °°ÀºÂÊ´ëÇ×±Ù
  • muscarinic antagonist
    ¹«½ºÄ«¸°´ëÇ×Á¦
  • narcotic antagonist
    ¸¶¾à´ëÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±ÙÀ°´ëÇ×Á¦
  • opioid antagonist
    ¾ÆÆíÀ¯»ç¹°Áú´ëÇ×Á¦
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò
  • allosteric enzyme
    ¾Ë·Î½ºÅ׸®È¿¼Ò
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • H2 receptor antagonist
    H2 ¼ö¿ëü ±æÇ×Á¦µé
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic antagonist
    ¾ËÆÄ¾Æµå·¹³¯¸°±æÇ×Á¦
  • androgen antagonist
    ³²¼ºÈ£¸£¸ó ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú, ±æÇ×±Ù, ±æÇ×¾à.
  • heavy metal antagonist
    Á߱ݼӱæÇ×¾à(̡˻ËÛ˻̰Ëâ).
  • heavy metal antagonist
    Á߱ݼӱæÇ×¾à(ñìÐÝáÕÑÏù÷å·).
  • ACE : angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò.
  • ACE=> angiotensin converting enzyme
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò(ï®üµý£áÈ)
  • ACEI : angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦(ï®ü½ý£áÈåäð¤ð¥).
  • Converting enzyme
    Àüȯȿ¼Ò(ï®üµý£áÈ)
  • ELISA => enzyme-linked immunosorbent assay
    ¿¤¶óÀÌÀÚ
  • EMMIA => enzyme modulator mediated immunoassay
    È¿¼ÒÁ¶Àý¸Å°³¸é¿ªÃøÁ¤
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adrenergic antagonist
    ¾Æµå·¹³¯¸° ±æÇ×¹°Áú
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°¼º ±æÇ×Á¦
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic antagonist
    ¾ËÆÄ¾Æµå·¹³¯¸°±æÇ×Á¦
  • androgen antagonist
    ³²¼ºÈ£¸£¸ó ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú, ±æÇ×±Ù, ±æÇ×¾à.
  • antagonist
    ±æÇ×Á¦
  • associated antagonist
    °ø¾×±æÇ×¹°Áú.
  • benzodiazepine receptor antagonist(s)
    º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ ¼ö¿ëü ±æÇ×Á¦
  • beta-adrenergic antagonist
    º£Å¸ ¾Æµå·¹³¯¸°¼º ÀúÇØÁ¦
  • calcium antagonist
    Ä®½·±æÇ×Á¦.
  • calcium channel antagonist,blocker
    Ä®½·Åë·Î ±æÇ×Á¦( -÷×ÖØ ÑÏù÷ð¥),Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • competitive antagonist
    °æÀï±æÇ×¹°Áú(¡­Úªòõ).
  • contralateral antagonist
    ¹Ý´ëÃø±æÇ×±Ù
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • enzyme-linked immunoelectrotransfer blot (EITB)
    È¿¼Ò¸é¿ªÀÌÀû¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • cholinergic antagonist
    Äݸ°±æÇ×Á¦(ÑÏù÷ð¥)
  • gibberellin antagonist
    Áö¹ö·¼¸° ±æÇ×Á¦(ÑÏù÷ð¥)
  • irreversible antagonist
    ºñ°¡¿ª ±æÇ×Á¦(ުʦæ½ÑÏù÷ð¥)
  • metabolic antagonist
    ´ë»ç¼º ±æÇ×Á¦(ÓÛÞóàõÑÏùòð¥))
  • activating enzyme
    "ºÎȰȿ¼Ò (Ý·üÀý£áÈ), Ȱ¼ºÈ­È¿¼Ò (üÀàõûùý£áÈ)"
  • acyl activating enzyme
    ¾Æ½ÇºÎȰȿ¼Ò (Ý·üÀý£áÈ)
  • acyl enzyme
    ¾Æ½ÇÈ¿¼Ò(ý£áÈ)
  • acyl enzyme intermediates
    ¾Æ½ÇÈ¿¼Ò Áß°£Ã¼(ñéÊàô÷)
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò(îêëëý£áÈ)
  • alteration enzyme
    º¯ÇüÈ¿¼Ò(ܨúþý£áÈ)
  • ambiquitous enzyme
    ¾çÁ¸È¿¼Ò(å»ðíý£áÈ)
  • amino acid activating enzyme
    ¾Æ¹Ì³ë»ê(ß«) Ȱ¼ºÈ­(üÀàõûù) È¿¼Ò(ý£áÈ)
  • amplifier enzyme
    ÁõÆøÈ¿¼Ò(ñòøëý£áÈ)
  • analogous enzyme variants
    À¯»çÈ¿¼Ò º¯ÀÌÇü(×¾ÞÄý£áÈܨì¶úþ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú
  • ELISA [=enzyme-linked immunosorbent assay]
    ELIZA, ¿¤¸®ÀÚ
  • enzyme
    È¿¼Ò
  • enzyme-linked immunosorbent assay [=ELISA]
    ELISA, ¿¤¸®ÀÚ
  • proteolytic enzyme
    ´Ü¹éÁúºÐÇØÈ¿¼Ò
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
antag antagonist
CA anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can...
FAA folic acid antagonist; formaldehyde, acetic acid, alcohol
EIA electroimmunoassay; enzyme immunoassay; enzyme-linked immunosorbent assay; equine infectious anemia;...
PACE Pacing and Clinical Electrophysiology; paired basic amino acid cleaving enzyme; personalized aerobic...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Ant Antagonist
CA calcium antagonist
GnRH-A GnRH antagonist
H2-RA Histamine-2 receptor antagonist
IL 1ra IL 1 receptor antagonist
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • 5-HT1 receptor antagonist
    5-HT1 ¼ö¿ë±â ±æÇ×Á¦
    ÀÏÂïÀÌ 5-hydroxytry
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦, ±æÇ× ¹°Áú, ±æÇ×±Ù, ±æÇ× ¾à
    ¹Ý´ë¾î=agonist. µ¿±Ù±ºÀ̳ª ÁÖµÈ ¿îµ¿±Ù¿¡ ¹Ý´ëµÇ´Â ±â´ÉÀ» ÇÏ´Â ±ÙÀ°. ¾à¸®Çп¡¼­´Â ´Ù¸¥ ¾à¹°ÀÇ È¿´ÉÀ» °¨¼Ò½ÃŰ´Â ¾à¹°À̳ª µ¿ÀÏÇÑ ¼ö¿ë±â¸¦ ÀÚ±ØÇÏ¿© »ý¼ºÇÏ´Â ¹°ÁúÀ» ÀǹÌÇÑ´Ù. ´Ù¸¥ ¾à¹°, ¹°ÁúÀÇ ÀÛ¿ëÀ» »ý¹°ÇÐÀû ¹ÝÀÀÀ» À¯µµÇÏÁö ¾Ê°í ¼¼Æ÷ ¸®¼ÁÅÍ¿¡ °áÇÕÇÏ¿©, °¨¾à ¶Ç´Â ¹«È¿·Î ÇÏ´Â ¾à¹°, ¹°Áú.
  • antagonist tooth
    ´ëÇÕÄ¡
  • competitive antagonist
    °æÀï ±æÇ× ¹°Áú
  • enzymic antagonist
    È¿¼Ò ±æÇ×Á¦
  • folic acid antagonist
    ¿±»ê ±æÇ×Á¦
  • hormone antagonist
    Ç×È£¸£¸ó ¾à, Ç×È£¸£¸ó ¹°Áú
  • metabolic antagonist
    ´ë»ç ±æÇ×Á¦
  • narcotic antagonist
    ¸¶¾à ±æÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±Ù ±æÇ×Á¦
  • pyrimidine antagonist
    ÇǸ®¹Ìµò ±æÇ×Á¦
  • serotonin antagonist
    ¼¼·ÎÅä´Ñ ±æÇ×Á¦
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅٽŠÀüȯ È¿¼Ò
  • angiotensin-converting enzyme
    ¾ÈÁö¿ÀÅٽŠÀüȯ È¿¼Ò
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
enzyme antagonist An antimetabolite or inhibitor of enzyme action.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
aldosterone antagonist An agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents, e.g., spironolactone, are useful in treating the hypertension of primary hyperaldosteronism, or the sodium retention of secondary hyperaldosteronism.
(05 Mar 2000)
antagonist <pharmacology> A substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response.
Origin: Gr. Antagonistes = an opponent
(18 Nov 1997)
associated antagonist One of two muscles or groups of muscles which pull in nearly opposite directions, but which, when acting together, move the part in a path between their diverging lines of action.
(05 Mar 2000)
beta-adrenoreceptor antagonist A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
calcium antagonist calcium channel-blocking agent
calcium channel antagonist <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
mixed opioid agonist-antagonist <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type.
(13 Nov 1997)
competitive antagonist An antimetabolite.
(05 Mar 2000)
muscarinic antagonist Drugs which bind with muscarinic cholinergic receptors but do not activate them, thus preventing access to acetylcholine; examples include atropine, scopolamine, propantheline, and pirenzepine.
(05 Mar 2000)
H2 antagonist <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells.
Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers.
Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac).
(27 Sep 1997)
insulin antagonist Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin.
(09 Oct 1997)
oestrogen antagonist <pharmacology> A drug or compound which inhibit or antagonise the action or biosynthesis of oestrogen.
Tamoxifen also has agonist or stimulatory actions as well as blocking effects. There are also selective oestrogen-receptor modulators (SERMs). For example, raloxifene (trade name Evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus.
(12 May 2002)
folate antagonist <pharmacology> One of a group of substances which blocks the formation of nucleotides that require the presence of folate (one of the B vitamins) before they can be made. The substance does this by blocking key steps in the reaction sequence. These substances are often used to treat cancer because fast-growing cancerous cells usually need to use the blocked reactions more than normal cells.
(09 Oct 1997)
folic acid antagonist <pharmacology> A chemical which inhibits a cells capacity to use folic acid and so prevent cell division, for example methotrexate.
See: chemotherapy.
(12 Nov 1997)
acetyl-activating enzyme A ligase that catalyses the reaction of acetate and CoA and ATP to form AMP, pyrophosphate, and acetyl-CoA. A key step in the activation of acetate.
Synonym: acetate thiokinase, acetate-CoA ligase, acetyl-activating enzyme, acetyl-CoA synthetase.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    Àû´ë
  • antagonist
    Àû´ëÀÚ;´ë¸³ÀÚ
  • Temin enzyme
    Å׹Πȿ¼Ò(RNA¿¡¼­ DNA¸¦ ¸¸µå´Â ¿ªÀü»ç È¿¼Ò)
  • enzyme
    È¿¼Ò
  • enzyme detergent
    È¿¼Ò ¼¼Á¦
  • enzyme engineering
    È¿¼Ò °øÇÐ(È¿¼Ò(ÀÛ¿ë)ÀÇ ³ó°ø¾÷¿¡ÀÇ ÀÀ¿ë)
  • respiratory enzyme
    È£ÈíÈ¿¼Ò
  • restriction enzyme
    Á¦ÇÑ È¿¼Ò(µÎÁÙ »ç½½ DNA¸¦ ƯÁ¤ ºÎÀ§¿¡¼­ Àý´ÜÇÏ´Â È¿¼Ò)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á